Amy Ko

962 total citations
38 papers, 699 citations indexed

About

Amy Ko is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Amy Ko has authored 38 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Amy Ko's work include Lung Cancer Treatments and Mutations (16 papers), Colorectal Cancer Treatments and Studies (9 papers) and Cancer Treatment and Pharmacology (9 papers). Amy Ko is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Colorectal Cancer Treatments and Studies (9 papers) and Cancer Treatment and Pharmacology (9 papers). Amy Ko collaborates with scholars based in United States, United Kingdom and Spain. Amy Ko's co-authors include Ann Mullally, Edwin Chen, Shannon Elf, Emily A. Rosen, Nouran S. Abdelfattah, Rebekka K. Schneider, Mark A. Socinski, Silvia Giannini, Markus F. Renschler and Zuzana Tóthová and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Amy Ko

38 papers receiving 691 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy Ko United States	12	312	278	262	201	122	38	699
Cristina Panaroni United States	14	129 0.4×	248 0.9×	377 1.4×	231 1.1×	106 0.9×	31	908
María José Larráyoz Spain	19	268 0.9×	417 1.5×	405 1.5×	148 0.7×	38 0.3×	34	801
Andres Sirulnik United States	13	452 1.4×	502 1.8×	593 2.3×	191 1.0×	47 0.4×	21	990
Andrea L. Dewar Australia	10	256 0.8×	426 1.5×	161 0.6×	294 1.5×	95 0.8×	11	796
Claudiu Cotta United States	16	123 0.4×	182 0.7×	294 1.1×	133 0.7×	58 0.5×	50	638
Stéphanie Struski France	16	134 0.4×	171 0.6×	264 1.0×	112 0.6×	76 0.6×	30	596
Safa Karandish United States	11	395 1.3×	524 1.9×	193 0.7×	136 0.7×	106 0.9×	13	733
JinJuan Yao United States	10	196 0.6×	229 0.8×	256 1.0×	101 0.5×	49 0.4×	25	508
Nicola Foot United Kingdom	14	213 0.7×	481 1.7×	402 1.5×	200 1.0×	40 0.3×	25	837
Alexey Bersenev United States	14	238 0.8×	228 0.8×	450 1.7×	230 1.1×	31 0.3×	24	838

Countries citing papers authored by Amy Ko

Since Specialization

Citations

This map shows the geographic impact of Amy Ko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Ko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Ko more than expected).

Fields of papers citing papers by Amy Ko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Ko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Ko. The network helps show where Amy Ko may publish in the future.

Co-authorship network of co-authors of Amy Ko

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Ko. A scholar is included among the top collaborators of Amy Ko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Ko. Amy Ko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gridelli, Cesare, Tianlei Chen, Amy Ko, et al.. (2018). nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial. Drug Design Development and Therapy. Volume 12. 1445–1451. 7 indexed citations

Cortés, Javier, José Manuel Pérez-García, Yin Wan, et al.. (2018). Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis. Clinical Breast Cancer. 18(5). e919–e926. 9 indexed citations

Elf, Shannon, et al.. (2017). Functional and Molecular Basis of Thrombopoietin Receptor Activation By Mutant Calreticulin. Blood. 130. 382. 1 indexed citations

Morgensztern, Daniel, Mary O’Brien, Teng Jin Ong, et al.. (2017). MA08.06 Impact of Depth of Response (DpR) on Survival in Patients with Advanced NSCLC Treated with First-Line Chemotherapy. Journal of Thoracic Oncology. 12(1). S387–S388. 3 indexed citations

Thomas, Michael, David R. Spigel, Robert M. Jotte, et al.. (2017). <em>nab</em>-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy. PubMed. Volume 8. 207–216. 5 indexed citations

Elf, Shannon, Nouran S. Abdelfattah, Edwin Chen, et al.. (2016). Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discovery. 6(4). 368–381. 189 indexed citations

George, Ben, Karen Kelly, Amy Ko, et al.. (2016). Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) in solid tumors: results from the pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) cohorts. Annals of Oncology. 27. vi363–vi363. 2 indexed citations

Gridelli, Cesare, Tianlei Chen, Amy Ko, et al.. (2016). P1.48: nab-Paclitaxel + Carboplatin in Advanced Non-Small Cell Lung Cancer: Outcomes in Elderly Patients With Squamous Histology. Journal of Thoracic Oncology. 11(10). S213–S213. 1 indexed citations

George, Ben, Karen Kelly, Amy Ko, et al.. (2016). P1.46: Phase I Study of Nivolumab + Nab-Paclitaxel in Solid Tumors: Preliminary Analysis of the Non-Small Cell Lung Cancer Cohort. Journal of Thoracic Oncology. 11(10). S211–S212. 3 indexed citations

10.

Gridelli, Cesare, Amy Ko, Mary O’Brien, et al.. (2016). 216PD: nab-Paclitaxel + carboplatin (nab-P/C) in advanced non-small cell lung cancer (NSCLC): outcomes in elderly patients (pts) with squamous (SCC) histology. Journal of Thoracic Oncology. 11(4). S154–S155. 2 indexed citations

11.

Hirsh, Vera, Amy Ko, Richard Pilot, Markus F. Renschler, & Mark A. Socinski. (2016). Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes. Clinical Lung Cancer. 17(5). 367–374. 27 indexed citations

12.

Langer, Corey J., Vera Hirsh, Katayoun I. Amiri, et al.. (2016). Quality of life (QoL) by response: An interim analysis of patients (pts) with squamous (SCC) NSCLC treated with nab-paclitaxel/carboplatin (nab-P/C) induction therapy in the phase III ABOUND.sqm study.. Journal of Clinical Oncology. 34(7_suppl). 63–63. 1 indexed citations

13.

Chen, Edwin, Jong Sook Ahn, Lawrence J. Breyfogle, et al.. (2015). RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. Cell Reports. 13(11). 2345–2352. 24 indexed citations

14.

Liang, Caihua, Ling Li, Amy Ko, et al.. (2015). The treatment patterns, efficacy, and safety of nab®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis. BMC Cancer. 15(1). 1019–1019. 23 indexed citations

15.

Ko, Amy, Leila Chaieb, Takashi Koyama, et al.. (2014). The POU Factor Ventral Veins Lacking/Drifter Directs the Timing of Metamorphosis through Ecdysteroid and Juvenile Hormone Signaling. PLoS Genetics. 10(6). e1004425–e1004425. 23 indexed citations

16.

Langer, Corey J., Vera Hirsh, Amy Ko, Markus F. Renschler, & Mark A. Socinski. (2014). Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Renal Impairment. Clinical Lung Cancer. 16(2). 112–120. 32 indexed citations

17.

Reni, Michele, Daniel D. Von Hoff, E. Gabriela Chiorean, et al.. (2013). CA19-9 Decrease and Kinetics in a Randomized Phase III Trial (MPACT) of Weekly Nab-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer. Annals of Oncology. 24. iv31–iv31. 2 indexed citations

18.

Rabe, Eberhard, et al.. (2010). Incidence of Varicose Veins, Chronic Venous Insufficiency, and Progression of the Disease in the Bonn Vein Study II. Journal of Vascular Surgery. 51(3). 791–791. 43 indexed citations

19.

Ko, Amy, Josep Tabernero, Fernando Rivera, et al.. (2010). Phase II study of telatinib (T) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced cancer of the stomach (G) or gastro-esophageal junction (GEJ).. Journal of Clinical Oncology. 28(15_suppl). e14575–e14575. 5 indexed citations

20.

Venook, Alan P., Amy Ko, Margaret A. Tempero, et al.. (2008). Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. Journal of Clinical Oncology. 26(15_suppl). 15545–15545. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact